focus -WSS

focus

author：Wikipedia 2025-10-01 02:28:24 - browse：22

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Biden warns of ‘dark winter’ during final presidental debate

leisure time

WSS

The battle over 'scope creep' and who gets to be called 'doctor'

STAT Summit: How a Chicago ER doctor tackles gun violence

STAT Summit: How a Chicago ER doctor tackles gun violence

Hospital price transparency does save money, advocate argues

Solve the antibiotic resistance crisis with preventive drugs

Lawmakers consider Medicare pay reforms for doctors

leisure time

focus

explore

Alkermes shareholders re

Hospital price transparency does save money, advocate argues

Activists slam private health insurers over coverage restrictions

STAT Summit: Michael J. Fox on progress in Parkinson's research

Medical records are filled with copy

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Jerome Adams on the need for new antivirals for Covid

STAT Report: Patient voices and perspectives

Dobbs anniversary: the lost opportunity of abortion as health care

What causes rare myocarditis in young men after Covid vaccines?

explore

CEOs share strategies for surviving biotech slump

Researchers explore possible ties between long Covid, menopause

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Impact of Dobbs ruling felt at reproductive medicine meeting

Studies point to risks of excluding people with obesity from drug trials

UHS says company favors patients whose insurance pays more

leisure time

focus

entertainment

hotspot